misleading statements

Class action lawsuit filed against BBWI alleging executives made false statements about growth strategy results. Coverage period: June 4, 2024 to November 19, 2025.

Class action lawsuit filed against $BSX alleging executives made false statements about U.S. electrophysiology segment sustainability, concealing competitive pressures and regulatory headwinds.

BellRing Brands faces securities lawsuits alleging misrepresented sales growth driven by inventory stockpiling. Lead plaintiff deadline: March 23, 2026.

RegenxBio faces securities class action alleging misleading RGX-111 gene therapy claims; investors have until April 14, 2026 to file.

Investors in $MREO have until April 6, 2026 to join securities class action alleging misleading statements about failed Phase 3 setrusumab trials.

Rosen Law Firm files class action against $BSX over alleged false statements regarding U.S. Electrophysiology segment sustainability, resulting in earnings miss and weak guidance.

Rosen Law Firm urges PomDoctor investors to join securities class action alleging fraud, stock manipulation, and insider selling. April 7, 2026 lead plaintiff deadline.

Picard Medical faces securities fraud lawsuit alleging stock manipulation through social media misinformation, insider dumping, and artificial trading. Investors have until April 13, 2026 to join class action.

Ultragenyx faces a securities class action alleging misrepresentations about its setrusumab drug's efficacy for osteogenesis imperfecta. Affected investors have until April 6, 2026 to serve as lead plaintiff.

Class action lawsuit filed against $EOSE for allegedly concealing production ramp failures, battery line downtime, and quality delays from November 2025 to February 2026.

Rosen Law Firm urges $INO investors to join class action lawsuit alleging false statements about manufacturing deficiencies and regulatory prospects.

Law firm launches class action against $NAVN over alleged failure to disclose surge in sales and marketing expenses following October 2025 offering.

Gross Law Firm sues Oracle for alleged false AI infrastructure statements; shareholders who bought stock June-December 2025 can claim damages by April 6, 2026.

The Gross Law Firm reminds shareholders of March 13, 2026 deadline to seek lead plaintiff status in securities fraud lawsuit against $BBWI over alleged false growth guidance.

The Gross Law Firm filed a class action lawsuit against $BRBR, alleging misrepresented organic sales growth and downplayed competitive pressures in ready-to-drink category.

Hagens Berman sues Corcept Therapeutics for allegedly misleading investors about relacorilant's FDA prospects. Stock crashed 50% after Complete Response Letter.

Class action filed against Mereo BioPharma over allegedly false statements regarding failed Phase 3 clinical trials, covering $MREO investors from June 2023 to December 2025.

Law firm files class action against Ramaco Resources alleging executives misrepresented Brook Mine development progress, harming shareholders between July-October 2025.

Class action lawsuit filed against Corcept Therapeutics for allegedly making false claims about relacorilant drug's clinical strength while concealing FDA regulatory concerns.

Law firm Levi & Korsinsky files class action against Boston Scientific, citing misleading statements. Stock tumbled 17.6% after disappointing Q4 2025 earnings and weak 2026 guidance.